Market Mover | Eli Lilly Shares Rise 4% as its Weight Loss Drug Reduces Heart Failure Risk in Trial
Market Mover | Eli Lilly Shares Rise 4% as its Weight Loss Drug Reduces Heart Failure Risk in Trial
August 1, 2024 - $Eli Lilly and Co (LLY.US)$shares increased 4.11% to $837.36 in trading on Thursday.
2024年8月1日 - $礼来 (LLY.US)$周四交易中股价上涨4.11％，至837.36美元。
Eli Lilly announced today its weight-loss drug tirzepatide could significantly improve heart failure symptoms and physical limitations, reducing the risk of heart failure outcomes by 38% compared to placebo in phase 3 clinical trial. The company will submit results to the FDA and other regulatory agencies starting later this year.
艾力礼今日宣布，其减重药物tirzepatide在3期临床试验中可以显著改善心衰症状和身体功能，相比安慰剂降低心衰终局风险38%。公司将于今年晚些时候向FDA和其他监管机构提交结果。
Tirzepatide is marketed as Mounjaro for diabetes treatment and Zepbound for weight loss and is administered by injection.
Tirzepatide作为治疗糖尿病的Mounjaro和用于减肥的Zepbound的市场，需通过注射给药。
In addition, Morgan Stanley Wealth Management increases internally held portfolio weights in Eli Lilly.
此外，摩根士丹利财富管理部门增加了对伊莱利利公司内部持有投资组合的权重。